Company intelligence / Profile preview

Shift Pharmaceuticals

Overland Park, Kansas, United Statesshiftpharmaceuticals.com ↗

Ownership: Private
Development stage: Other

Overview

Shift Pharmaceuticals develops antisense oligonucleotide therapeutics targeting the root causes of genetic neuromuscular diseases. Its lead program for spinal muscular atrophy has advanced through preclinical development with significant NIH grant support; IND-enabling studies are ongoing as of late 2023. No clinical trial results have been published yet

Therapeutic areas: Neurology
Modalities: Antisense oligonucleotide
Industry: Biotech

Drug pipeline

1 asset

SHC1A-012

Preclinical

Partnerships

University of Missouri (technology licensing/collaboration)National Institutes of Health/NINDS/Blueprint for Neuroscience Research grant partnershipCharcot-Marie-Tooth Association collaboration on CMT1A therapy development

Beyond the preview

Go deeper on Shift Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shift Pharmaceuticals.

Explore the full profile